{"id":39408,"date":"2026-08-10T09:11:00","date_gmt":"2026-08-10T13:11:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=39408"},"modified":"2026-08-08T14:00:04","modified_gmt":"2026-08-08T18:00:04","slug":"the-salt-change-trap-when-a-new-patent-buys-you-nothing","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/the-salt-change-trap-when-a-new-patent-buys-you-nothing\/","title":{"rendered":"The Salt Change Trap: When a New Patent Buys You Nothing"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

A drug goes off patent. The originator swaps the salt form, files a new patent, and tells investors the franchise is protected into the next decade. Sometimes that holds up in court. Often it does not. The difference between the two outcomes is not a matter of luck. It is a matter of chemistry, prior art, and whether the new salt actually did something the old one could not.<\/p>\n\n\n\n

This article works through the legal test for salt patent validity, walks through the cases that decided it, and lays out what the pattern means for anyone tracking exclusivity dates, building a Paragraph IV challenge, or deciding whether a salt-form patent is worth the filing fee. Where a fact, figure, or holding appears below, it comes from a reported court decision, an FDA record, or a published industry report, cited in the numbered list at the end.<\/p>\n\n\n\n

What Is a Salt Change Patent, and Why Do Drugmakers File Them?<\/h2>\n\n\n\n

Short answer:<\/strong> A salt change patent claims a new acid or base form of an existing drug molecule, chosen for reasons that can include stability, solubility, or manufacturing convenience, filed after the original compound patent to extend exclusivity on the same active ingredient.<\/p>\n\n\n\n

Most small-molecule drugs are not administered as the pure “free base” or “free acid” form of the active molecule. They are administered as a salt: an acid or base paired with the parent compound to improve how it dissolves, how it is absorbed, and how stable it stays on a shelf. Sertraline is sold as sertraline hydrochloride. Amlodipine is sold as amlodipine besylate. Duloxetine is sold as duloxetine hydrochloride. The choice of salt is a real pharmaceutical decision, made early in development, usually covered by a genus claim in the original compound patent that lists dozens of “pharmaceutically acceptable salts” without picking a winner.<\/p>\n\n\n\n

The trap shows up later. As the original composition-of-matter patent nears expiration, the company returns to the salt-selection question, picks a different counter-ion, and files a new patent claiming that specific salt. If the new salt is genuinely inventive, the patent can hold. If it is one of a handful of routine candidates any formulation chemist would have screened as a matter of course, a court is likely to call it obvious and throw it out, along with whatever exclusivity it was meant to buy.<\/p>\n\n\n\n

Why Drugmakers Change Salts After the Original Compound Patent<\/h3>\n\n\n\n

There are two very different motives behind a late-stage salt patent, and they produce two very different outcomes in litigation.<\/p>\n\n\n\n

    \n
  • Genuine reformulation need: the original salt has a real problem, such as poor stability at higher doses, hygroscopicity that complicates manufacturing, or an inability to resolve a racemic mixture into its active form. A new salt solves that problem and enables something the old salt could not do.<\/li>\n\n\n\n
  • Portfolio management: the original salt works fine, the compound patent is expiring, and a new salt is filed primarily to generate a fresh Orange Book listing and a fresh round of Paragraph IV litigation risk for generic entrants.<\/li>\n<\/ul>\n\n\n\n

    Courts do not accept the second motive as a defense, but they also do not presume it. Each case turns on the specific prior art and the specific evidence of what made the chosen salt different, which is why identical fact patterns, a besylate salt in one case, a bisulfate salt in another, can produce opposite rulings.<\/p>\n\n\n\n

    Salt Forms, Polymorphs, and Enantiomers: What Is Actually Different<\/h3>\n\n\n\n

    These three terms get conflated constantly in casual pharma writing, and the conflation causes real analytical errors. They are not the same kind of change, and courts do not treat them the same way.<\/p>\n\n\n\n

      \n
    • Salt form<\/strong>: pairing the active molecule with a different acid or base counter-ion (besylate instead of maleate, mesylate instead of hydrochloride). The core molecule is unchanged.<\/li>\n\n\n\n
    • Polymorph<\/strong>: the same molecule, or the same salt, crystallizing in a different solid-state arrangement. Same chemical formula, different crystal lattice, which can change solubility and stability without changing the salt at all.<\/li>\n\n\n\n
    • Enantiomer<\/strong>: isolating one of two mirror-image forms of a chiral molecule that was previously sold as a racemic mixture of both. This is a genuine structural change to the active ingredient, not a formulation choice.<\/li>\n<\/ul>\n\n\n\n

      Novartis’ Glivec dispute concerned a polymorph of an already-patented salt, not a new salt itself. Sanofi’s Plavix patent concerned an enantiomer paired with a specific salt. Pfizer’s Norvasc patent concerned a pure salt-form change with no polymorph or enantiomer question involved. Confusing these categories when researching a drug’s exclusivity position is one of the more common and consequential mistakes made when reading an Orange Book listing.<\/p>\n\n\n\n

      Common Pharmaceutically Acceptable Salts and Why Each Gets Chosen<\/h4>\n\n\n\n
        \n
      • Hydrochloride: the default first choice for basic drug molecules, cheap, well characterized, and the subject of decades of prior art.<\/li>\n\n\n\n
      • Besylate (benzenesulfonate): chosen when hydrochloride or maleate salts show poor stability or hygroscopicity at manufacturing scale.<\/li>\n\n\n\n
      • Mesylate (methanesulfonate): common for compounds needing higher aqueous solubility than a hydrochloride salt provides.<\/li>\n\n\n\n
      • Bisulfate: used where it improves crystallization behavior during resolution of a chiral compound, as in Plavix.<\/li>\n<\/ul>\n\n\n\n

        The Legal Test: When Does a New Salt Count as an Invention?<\/h2>\n\n\n\n

        Short answer:<\/strong> Under 35 U.S.C. Section 103, a new salt is unpatentable if a person of ordinary skill in the art would have found it obvious to try, based on prior art disclosing the parent compound and standard salt-screening references, unless the patentee can show unexpected results that a routine screen would not have predicted.<\/p>\n\n\n\n

        Salt selection sits in an uncomfortable spot in patent law. It is real pharmaceutical work, requiring lab time, testing, and judgment. It is also, in the routine case, a known and finite process: pharmaceutical scientists have a standard list of counter-ions they screen against solubility, stability, hygroscopicity, and melting point, and that list has been published and taught since the 1970s. Whether a specific salt selection clears the bar for patentability depends on how the facts map onto that tension.<\/p>\n\n\n\n

        The Graham Factors Under 35 U.S.C. Section 103<\/h3>\n\n\n\n

        Every obviousness analysis, salt patents included, runs through the same four-part framework the Supreme Court set out in Graham v. John Deere: the scope and content of the prior art, the differences between the prior art and the claims, the level of ordinary skill in the field, and any objective evidence bearing on obviousness, such as commercial success, long-felt unmet need, or results nobody expected. For a salt patent, the second and fourth factors do almost all the work. A generic salt genus claim in an earlier patent, combined with a standard salt-selection reference, usually supplies the prior art. The fight is over whether the specific salt chosen behaved in a way nobody could have predicted from that starting point.<\/p>\n\n\n\n

        KSR v. Teleflex and the Collapse of the Rigid TSM Test<\/h3>\n\n\n\n

        Before 2007, the Federal Circuit required clear evidence of a specific “teaching, suggestion, or motivation” in the prior art before a combination could be called obvious. The Supreme Court’s 2007 decision in KSR International Co. v. Teleflex Inc. rejected that rigid rule in favor of a more flexible, common-sense inquiry, one that asks whether a skilled artisan facing a finite, identified set of predictable options would have been motivated to try each of them.[4]<\/sup> Salt selection is exactly the kind of finite, predictable set KSR had in mind. If a prior art patent discloses the parent compound and a genus of acceptable salts, and a standard reference lists the handful of counter-ions ordinarily screened for a given class of molecule, choosing one of them looks a great deal like the routine optimization KSR said does not deserve a patent.<\/p>\n\n\n\n

        The Berge Reference: Why “Pharmaceutical Salts” Follows Every Salt Case Into Court<\/h3>\n\n\n\n

        A single 1977 journal article shows up in nearly every reported salt-obviousness case: Berge, Bighley, and Monkhouse’s “Pharmaceutical Salts,” published in the Journal of Pharmaceutical Sciences.[12]<\/sup> It catalogs the acid and base addition salts commonly used in drug formulation and became, over decades of litigation, the standard proof that a defendant’s chosen salt sat on a known, finite list rather than in some unbounded universe of possibilities. When a generic challenger can point to a parent compound’s genus claim plus Berge, the patentee is fighting from a weak starting position and needs strong evidence of unpredictability to survive.<\/p>\n\n\n\n

        Objective Indicia Courts Weigh: Unexpected Results vs. Routine Verification<\/h4>\n\n\n\n

        The line courts draw again and again is between discovering something and confirming something. Testing a salt candidate to verify it behaves the way the prior art predicted is routine verification, not invention. Finding that a salt behaves in a way nothing in the prior art suggested, better stability at a dose nobody could reach before, a manufacturing process nobody could run before, is the kind of unexpected result that survives an obviousness challenge. The two Federal Circuit cases below show how that line gets drawn in opposite directions on very similar fact patterns.<\/p>\n\n\n\n

        Case Study: Pfizer v. Apotex and the Besylate Salt That Added Nothing<\/h2>\n\n\n\n

        Short answer:<\/strong> The Federal Circuit invalidated Pfizer’s patent on amlodipine besylate, the salt form of Norvasc, in 2007, reversing three separate district court rulings and holding that the besylate salt was an obvious, routine selection from a known list of candidates disclosed in an earlier Pfizer patent and the Berge reference.<\/p>\n\n\n\n

        This is the case every pharma IP team studies before filing a new salt patent, and for good reason. It shows a patentee losing not because the science was weak, but because the legal argument for unpredictability could not survive scrutiny of the actual lab record.<\/p>\n\n\n\n

        How Norvasc’s ‘303 Patent Was Built<\/h3>\n\n\n\n

        Pfizer’s earlier patent, the ‘909 patent, disclosed amlodipine and a genus of its pharmaceutically acceptable salts, without identifying the besylate salt by name. Pfizer originally marketed amlodipine as a maleate salt, then encountered manufacturing problems, tackiness and stickiness during tableting, and screened a list of alternative counter-ions to fix it. Besylate came out of that screen. Pfizer patented it specifically in the ‘303 patent, issued in 1989, arguing to the examiner that each salt imparts unique properties and that besylate was accordingly a distinct, non-obvious compound.[1]<\/sup><\/p>\n\n\n\n

        Why the Federal Circuit Reversed Three District Courts<\/h3>\n\n\n\n

        Apotex filed an abbreviated new drug application for generic amlodipine besylate and challenged the ‘303 patent as obvious over the ‘909 patent combined with Berge. Three different district court judges, hearing the case at different points, all found the patent valid, reasoning that salt behavior cannot be reliably predicted and that Pfizer would not have abandoned its investment in the maleate salt without a compelling reason.[1]<\/sup> The Federal Circuit disagreed. It found that Pfizer’s own laboratory notebooks showed a routine screening process: make each candidate salt, run standard tests for solubility, stability, and hygroscopicity, and compare the results against expectations set by the prior art. The court held that this was verification of predicted properties, not discovery of unpredictable ones, and that the ‘909 patent’s genus claim combined with Berge supplied everything a skilled chemist needed to arrive at besylate as one of a short list of reasonable candidates.[1]<\/sup><\/p>\n\n\n\n

        Timeline: The Norvasc Besylate Salt Litigation, 2003 to 2007<\/h4>\n\n\n\n
        Date<\/th>Event<\/th><\/tr>
        1989<\/td>The ‘303 patent issues, covering amlodipine besylate specifically.<\/td><\/tr>
        July 2003<\/td>Pfizer sues Apotex in the Northern District of Illinois after Apotex files an ANDA for generic amlodipine besylate.<\/td><\/tr>
        January 2006<\/td>Bench trial concludes; the district court finds the ‘303 patent not invalid for obviousness or anticipation.<\/td><\/tr>
        March 2007<\/td>The Federal Circuit reverses, holding the patent obvious in view of the ‘909 patent and the Berge reference.<\/td><\/tr>
        May 2007<\/td>The Federal Circuit denies Pfizer’s petition for rehearing en banc, over dissents from Judges Newman and Rader.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

        What the Ruling Means for Every Salt Selection Patent Filed Since<\/h3>\n\n\n\n

        Pfizer v. Apotex did not create a rule that all salt patents are invalid. It created a fact pattern that every subsequent salt case gets measured against: a genus disclosure in a prior patent, a standard salt reference, and a lab record showing routine screening rather than genuine surprise. Patentees who can show their chosen salt solved a problem the prior art gave no reason to expect it would solve have continued to win. Patentees whose internal records read like a checklist have continued to lose.<\/p>\n\n\n\n

        Case Study: Plavix and the Salt Change That Was Worth Billions<\/h2>\n\n\n\n

        Short answer:<\/strong> Sanofi’s patent on clopidogrel bisulfate, the active ingredient in Plavix, was upheld in litigation against Apotex because the bisulfate salt was tied to resolving a chiral compound into its active enantiomer, a technical problem the prior art did not solve, not to a routine salt swap on an already-isolated molecule.<\/p>\n\n\n\n

        Clopidogrel Bisulfate and the Chiral Resolution Problem<\/h3>\n\n\n\n

        Clopidogrel is the dextrorotatory enantiomer of a compound that, as a racemic mixture, had already appeared in earlier patent filings. Sanofi’s ‘265 patent claimed the isolated d-enantiomer specifically, in its bisulfate salt form, and the two elements were not independent choices.[3]<\/sup> The bisulfate salt was material to how the enantiomers could be separated and crystallized in a form stable and pure enough to manufacture at scale. That combination, an enantiomer separation problem plus a salt form that helped solve it, gave Sanofi a stronger unpredictability argument than a pure salt swap on an already-isolated molecule would have supported.<\/p>\n\n\n\n

        Why Apotex’s At-Risk Launch Cost 442 Million Dollars<\/h3>\n\n\n\n

        Apotex received FDA approval for a generic clopidogrel bisulfate ANDA in January 2006 and launched at risk in August 2006, while validity litigation with Sanofi and Bristol-Myers Squibb was still unresolved.[10]<\/sup> The district court granted Sanofi a preliminary injunction that August, and litigation continued for years afterward. In February 2012, following a 2011 Federal Circuit ruling upholding the damages award, Apotex paid 442,209,362 dollars to Sanofi and Bristol-Myers Squibb to satisfy the judgment for the harm caused by its at-risk launch.[10]<\/sup> Annual U.S. sales of clopidogrel 75 mg tablets were estimated at roughly 3.3 billion dollars at the time Apotex launched, which gives some sense of the exposure a generic company takes on when it bets on invalidity and loses.<\/p>\n\n\n\n

        Salt Selection vs. Chiral Resolution: Why Plavix Is Not a Counterexample to Norvasc<\/h4>\n\n\n\n

        It is tempting to read Norvasc and Plavix as contradictory rulings on salt patentability. They are not. Norvasc involved a salt change layered onto an already fully-characterized, already-isolated molecule, with a prior patent already disclosing a genus of acceptable salts for it. Plavix involved a salt tied directly to solving the harder problem of isolating one enantiomer from a racemate. The salt was not the invention standing alone. It was part of how the invention, the resolved enantiomer, got made and stayed stable. That distinction, salt as cosmetic afterthought versus salt as functionally necessary to the underlying advance, is the single most useful diagnostic question to ask about any late-stage salt patent.<\/p>\n\n\n\n

        Salt Patents vs. Polymorph Patents: The Novartis Glivec Precedent<\/h2>\n\n\n\n

        Short answer:<\/strong> India’s Supreme Court rejected Novartis’ patent application for the beta-crystalline polymorph of imatinib mesylate in 2013, holding that a new crystal form of an already-known and already-marketed salt did not meet the enhanced-efficacy standard required by Section 3(d) of India’s Patents Act, a standard significantly stricter than the obviousness test used in the United States.<\/p>\n\n\n\n

        Section 3(d) and India’s Higher Bar for Incremental Pharma Patents<\/h3>\n\n\n\n

        Section 3(d), added to India’s Patents Act in the 2005 amendments that brought India into compliance with TRIPS, specifically excludes from patentability the mere discovery of a new form of a known substance unless that new form demonstrates significantly enhanced efficacy over the known substance.[2]<\/sup> Novartis sought a patent not on imatinib or on imatinib mesylate, both already known, but on the beta-crystalline form of the mesylate salt, referred to in the litigation as beta-IM. India’s patent office, its appellate board, and ultimately its Supreme Court all rejected the application.<\/p>\n\n\n\n

        What “Enhanced Therapeutic Efficacy” Actually Requires<\/h3>\n\n\n\n

        Novartis argued that beta-IM showed a 30 percent increase in bioavailability. The Supreme Court found the comparison misleading: the 30 percent figure compared beta-IM against the free base of imatinib, which was never marketed because it was not soluble enough to use, rather than against the already-marketed mesylate salt.[13]<\/sup> Measured against the correct baseline, the drug patients were actually being asked to compare against, Novartis had not shown the kind of therapeutic advantage Section 3(d) requires. The Court was careful to note that this ruling did not bar all incremental pharmaceutical patents in India, only ones that fail to clear that specific efficacy bar.[12]<\/sup><\/p>\n\n\n\n

        Comparison Table: Salt and Polymorph Patentability Standards<\/h4>\n\n\n\n
        Jurisdiction<\/th>Governing Standard<\/th>Practical Effect on Salt or Polymorph Claims<\/th><\/tr>
        United States<\/td>35 U.S.C. Section 103 obviousness, Graham factors, post-KSR flexible analysis<\/td>Patentable if unexpected results rebut a prima facie obviousness case; routine screening results are not enough<\/td><\/tr>
        India<\/td>Section 3(d), Patents Act 1970 as amended in 2005<\/td>New forms of known substances are unpatentable absent proof of significantly enhanced therapeutic efficacy against the correct known form<\/td><\/tr>
        Canada<\/td>Common law obviousness plus a growing body of Federal Court “selection patent” precedent<\/td>Fact-specific; recent rulings have upheld well-evidenced salt and polymorph selections while striking overbroad ones<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

        How Courts Evaluate a Structurally Similar Salt Claim<\/h2>\n\n\n\n

        Short answer:<\/strong> Beyond salt-specific case law, courts apply a lead compound analysis borrowed from structural obviousness cases, asking first whether a skilled chemist would have selected the prior art compound as a starting point, and second whether there was a reason to make the specific modification claimed.<\/p>\n\n\n\n

        The Lead Compound Analysis: Takeda v. Alphapharm and Actos<\/h3>\n\n\n\n

        Takeda Chemical Industries, Ltd. v. Alphapharm Pty., Ltd. did not concern a salt directly, but its two-step framework shapes how courts think about any claim that a new pharmaceutical variant was obvious over a structurally close prior art compound.[5]<\/sup> Alphapharm argued that Takeda’s pioglitazone patent was obvious because a prior compound differed from pioglitazone by only a single methyl group. The Federal Circuit rejected the argument, holding that Alphapharm never showed a skilled chemist would have picked that specific prior compound as the starting point for further modification, and that the record in fact taught away from it because of toxicity concerns. The same two-step logic, would a skilled artisan have started here, and would they have had a reason to make this specific change, now runs through salt cases as well.<\/p>\n\n\n\n

        When a Paragraph IV Certification Becomes Sanctionable<\/h3>\n\n\n\n

        Takeda’s companion case against Mylan produced a lesson generic filers take seriously: courts can and do sanction a Paragraph IV certification that shifts its obviousness theory during litigation without ever explaining, in the certification itself, why a skilled artisan would have selected the asserted lead compound.[5]<\/sup> The district court in that case found Mylan’s certification baseless and awarded 16.8 million dollars in attorneys’ fees, a result the Federal Circuit affirmed. A weak salt-obviousness theory is not merely a losing argument. Filed carelessly, it is a fee-shifting risk.<\/p>\n\n\n\n

        Red Flags That Signal an Obvious Salt Patent<\/h4>\n\n\n\n
          \n
        • A prior patent already discloses a genus claim covering “pharmaceutically acceptable salts” of the same parent compound.<\/li>\n\n\n\n
        • The specification describes the salt-selection process as routine screening against standard parameters, without describing a specific problem the chosen salt uniquely solved.<\/li>\n\n\n\n
        • Internal lab notebooks or FDA correspondence describe the new salt as functionally equivalent to, or interchangeable with, the old one.<\/li>\n\n\n\n
        • The claimed advantage is manufacturing convenience alone, with no data showing a property the prior art gave no reason to expect.<\/li>\n<\/ul>\n\n\n\n

          The Orange Book Mechanics Behind Every Salt Patent Strategy<\/h2>\n\n\n\n

          Short answer:<\/strong> A new salt patent gets listed against the same drug product entry in the FDA’s Orange Book, triggering a fresh round of Paragraph IV certification risk, a possible 30-month stay if the brand sues within 45 days, and a 180-day exclusivity race among generic challengers.<\/p>\n\n\n\n

          How a New Salt Patent Gets Listed Against an Existing Drug<\/h3>\n\n\n\n

          Only drug substance, drug product, and method-of-use patents are eligible for Orange Book listing; manufacturing process patents are excluded.[9]<\/sup> A new salt patent typically lists as a drug substance patent, alongside whatever composition-of-matter and method-of-use patents already cover the product, and each ANDA filer must certify its position against every listed patent individually, whether that patent expires in two years or twenty.<\/p>\n\n\n\n

          Paragraph IV Certification and the 45-Day Countdown to a 30-Month Stay<\/h3>\n\n\n\n

          An ANDA applicant certifies to each Orange Book patent under one of four categories: the patent information is inaccurate, the patent has expired, the applicant will wait for expiration, or the patent is invalid or will not be infringed, the Paragraph IV route. A Paragraph IV certification triggers a 45-day window in which the patent holder can sue for infringement. If suit is filed within that window, the FDA is barred from granting final ANDA approval for 30 months from the date the patent holder received notice, regardless of how the litigation is proceeding, unless a court resolves the dispute first.[9]<\/sup> This stay is automatic. It requires no judicial finding on the merits, which is precisely why brand companies have every financial incentive to list any plausibly defensible patent, salt patents included, against a product generating hundreds of millions of dollars a quarter.<\/p>\n\n\n\n

          The 180-Day Exclusivity Race for the First Generic Challenger<\/h4>\n\n\n\n

          The first ANDA applicant to file a substantially complete Paragraph IV certification against a listed patent generally earns 180 days of market exclusivity against other generic filers, running from first commercial marketing or a favorable court decision, whichever comes first. On a drug with a billion dollars in annual U.S. sales, that window can be worth 150 to 400 million dollars, which is why a new salt patent listing often draws a wave of Paragraph IV filings within weeks of becoming public.<\/p>\n\n\n\n

          What Happens When a Salt Patent Is Delisted or Disclaimed<\/h3>\n\n\n\n

          When a court finds a listed patent invalid, or when the patentee files a statutory disclaimer rather than litigate a weak claim to judgment, the FDA removes the patent from the Orange Book and any pending 30-month stay tied to it ends. Generic applicants monitoring a salt patent’s litigation status, rather than only its nominal expiration date, routinely gain months or years of earlier visibility into a real launch date than the printed Orange Book entry alone would suggest.<\/p>\n\n\n\n

          Salt-Change Patents as an Evergreening Tactic: What the Data Shows<\/h2>\n\n\n\n

          Short answer:<\/strong> Independent analysis of the top-selling U.S. drugs found an average of 125 patent applications filed and 71 patents granted per drug, with 66 percent of applications filed after FDA approval, producing an average of 38 years of attempted exclusivity against a nominal 20-year patent term.<\/p>\n\n\n\n

          I-MAK’s Findings on Patent Thickets and Secondary Patents<\/h3>\n\n\n\n

          The nonprofit I-MAK’s Overpatented, Overpriced report examined twelve of the best-selling drugs in the United States and found a consistent pattern: a small number of primary patents cover the original invention, followed by a much larger number of secondary and tertiary patents covering formulations, salts, methods of use, and manufacturing processes, filed well after the drug reached the market.[6]<\/sup><\/p>\n\n\n\n

          \n

          “Pharmaceutical companies secure hundreds of patents to block competition because they can,” I-MAK concluded in its analysis of the twelve best-selling drugs, which averaged 125 patent applications filed and 71 patents granted per product, yielding roughly 38 years of attempted protection against a nominal 20-year term.[6]<\/sup><\/p>\n<\/blockquote>\n\n\n\n

          Humira, Keytruda, and the Pattern of Post-Approval Filing<\/h3>\n\n\n\n

          Individual drug figures from the same body of research show how far the pattern extends. Humira, on the market since 2002, has accumulated 132 patents blocking competition for up to 39 years. Keytruda has 180 patent applications filed and 78 granted, providing an attempted 37.3 years of protection, nearly double the 20-year period the patent system was designed to grant.[6]<\/sup> Salt-form patents are one tool inside this broader pattern, not the whole of it, but they follow the same underlying logic: file late, file often, and let the Paragraph IV process sort out which filings survive contact with a court.<\/p>\n\n\n\n

          How Many Patents Does the Average Blockbuster Really Carry?<\/h4>\n\n\n\n

          Across the ten top-selling U.S. drugs studied in a related I-MAK analysis, drugmakers filed an average of 140 patent applications per drug, 66 percent after FDA approval, resulting in an average of 74 granted patents per product, roughly four times the average patent count on the same drugs in Europe.[6]<\/sup> That gap between U.S. and European patent density is itself a useful signal: it tracks differences in how aggressively secondary and tertiary patents, salt claims among them, get pursued and defended across jurisdictions.<\/p>\n\n\n\n

          The Pendulum Swings Back: Recent Cases Where Salt Patents Held Up<\/h2>\n\n\n\n

          Short answer:<\/strong> Salt and polymorph patents have not become uniformly unpatentable since 2007. Several post-Norvasc rulings, in both the United States and Canada, have upheld salt-form patents where the record showed genuine, unpredictable technical benefit rather than routine screening.<\/p>\n\n\n\n

          Valeant v. Watson: When a Bupropion Salt Change Improved Stability<\/h3>\n\n\n\n

          A Southern District of Florida ruling, affirmed by the Federal Circuit, upheld Valeant’s patents covering a particular salt formation of the antidepressant bupropion after Watson Pharmaceuticals challenged them as obvious.[11]<\/sup> The court found no single anticipatory reference and, on the obviousness question, credited evidence that the chosen salt improved dosage-form stability enough to enable a once-daily formulation at higher strengths than the previously marketed salt could support. That functional benefit, not mere routine verification, was what distinguished the outcome from Norvasc.<\/p>\n\n\n\n

          Merck’s Januvia DHP Salt and the “Selection Patent” Defense<\/h3>\n\n\n\n

          In 2022, Canada’s Federal Court upheld Merck’s patent covering the dihydrogen phosphate salt of sitagliptin, the active ingredient in Januvia, in its crystalline monohydrate form, against a challenge from Pharmascience.[7]<\/sup> The prior art disclosed sitagliptin generally and specifically exemplified both a free base and a hydrochloride salt, but the court held that nothing in that prior art distinguished sitagliptin from the other compounds in its genus or gave a skilled formulator a specific reason to pursue further work on it. The court categorized the DHP salt patent as a valid “selection patent,” rejecting the argument that salt and polymorph patents are obvious as a categorical matter.[7]<\/sup><\/p>\n\n\n\n

          Lilly’s Cialis Salt Claim and Why Breadth Killed It<\/h4>\n\n\n\n

          Not every recent ruling has favored patentees. In October 2022, Canada’s Federal Court granted summary judgment against Eli Lilly on tadalafil claims extending to any “physiologically acceptable salt,” finding the claims invalid for overbreadth and insufficient disclosure. The lesson runs parallel to Norvasc: a claim broad enough to sweep in salts the specification never actually characterized or tested is vulnerable regardless of whether any individual salt within that scope might have been separately patentable.<\/p>\n\n\n\n

          How to Tell If Your Salt Patent Will Survive a Paragraph IV Challenge<\/h2>\n\n\n\n

          Short answer:<\/strong> A defensible salt patent needs documented, unpredictable technical benefit over the prior art salt, evidence the benefit was not something a routine screen would have anticipated, and a claim scope narrow enough to match what was actually tested.<\/p>\n\n\n\n

          Evidence That Supports Nonobviousness<\/h3>\n\n\n\n
            \n
          • Data showing a specific property, stability at a higher dose, resolution of a chiral mixture, a manufacturing process the old salt could not support, that nothing in the prior art predicted.<\/li>\n\n\n\n
          • A documented record showing the chosen salt was not simply the next item on a standard screening checklist.<\/li>\n\n\n\n
          • Commercial evidence, such as a formulation that only became viable because of the new salt, tying the invention to a real unmet need rather than a defensive filing calendar.<\/li>\n<\/ul>\n\n\n\n

            Common Mistakes That Doomed Salt Patents in Court<\/h3>\n\n\n\n
              \n
            • Claiming a broad genus of “acceptable salts” rather than the specific salt actually characterized and tested, the overbreadth problem that sank Lilly’s Cialis claims.<\/li>\n\n\n\n
            • Filing internal documentation that describes the new salt as functionally interchangeable with the old one, language that later becomes the generic challenger’s best evidence.<\/li>\n\n\n\n
            • Relying on a bare assertion that “each salt imparts unique properties,” the argument that failed Pfizer once the Federal Circuit examined the underlying lab record.<\/li>\n<\/ul>\n\n\n\n

              Questions to Ask Before You File a New Salt Patent<\/h4>\n\n\n\n
                \n
              • Does an earlier patent already disclose this compound with a genus claim covering pharmaceutically acceptable salts?<\/li>\n\n\n\n
              • Would a standard salt-screening reference have led a formulator to this specific counter-ion as one of a short, predictable list?<\/li>\n\n\n\n
              • Is there test data showing a property this salt has that the prior art gave no reason to expect?<\/li>\n\n\n\n
              • Does the claim language match the scope of what was actually tested, or does it reach further?<\/li>\n<\/ul>\n\n\n\n

                What This Means for Generic and Biosimilar Challengers<\/h2>\n\n\n\n

                Short answer:<\/strong> A late-stage salt patent listed shortly before the original composition-of-matter patent expires is a strong candidate for Paragraph IV challenge, particularly where the brand’s own prosecution history describes the salt selection as routine.<\/p>\n\n\n\n

                Building a Paragraph IV Case Against a Weak Salt Patent<\/h3>\n\n\n\n

                The strongest challenges follow the pattern that worked against Pfizer: locate the earlier genus-claim patent, pair it with a standard salt-selection reference such as Berge, and use the file history and any available lab notebooks to show the challenged salt was identified through routine screening rather than genuine discovery. Where the brand’s own patent specification argues, without supporting data, that the salt has unique properties, that language becomes evidence for the challenger, not the patentee.<\/p>\n\n\n\n

                Litigation Cost and Risk Calculus for ANDA Filers<\/h3>\n\n\n\n

                Complex Paragraph IV litigation involving a single patent can run 20 to 30 million dollars, a figure that shapes which challenges get filed and which patents get waited out instead. Some generic manufacturers deliberately choose a Paragraph III certification, agreeing to wait for a weak patent to expire rather than fight it, and then launch immediately after a competitor’s successful Paragraph IV challenge clears the same patent, sacrificing the 180-day exclusivity in exchange for avoiding litigation cost entirely.<\/p>\n\n\n\n

                Timeline: From Paragraph IV Notice to Generic Launch<\/h4>\n\n\n\n
                Stage<\/th>Typical Duration<\/th><\/tr>
                ANDA filing with Paragraph IV certification<\/td>Day 0<\/td><\/tr>
                Notice to patent holder<\/td>Within days of ANDA submission<\/td><\/tr>
                Window for brand to sue and trigger the 30-month stay<\/td>45 days from notice<\/td><\/tr>
                Automatic stay on final FDA approval, if suit is filed<\/td>Up to 30 months from notice<\/td><\/tr>
                First-filer exclusivity, if the challenge succeeds<\/td>180 days from launch or favorable judgment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

                Salt Change vs. Other Evergreening Tactics: A Comparison<\/h2>\n\n\n\n

                Short answer:<\/strong> Salt-form patents are one of several late-stage patenting tactics used to extend exclusivity, alongside formulation patents, method-of-use patents, and fixed-dose combinations, each with a different obviousness standard and a different litigation track record.<\/p>\n\n\n\n

                Salt Change vs. Polymorph vs. Formulation Patents<\/h3>\n\n\n\n

                Eli Lilly’s Cymbalta franchise illustrates how these tactics stack rather than substitute for one another. The core composition-of-matter patent on duloxetine hydrochloride expired in June 2013. A separate formulation patent covering the delayed-release enteric pellet technology extended protection toward 2017. Method-of-use patents tied to specific indications reached further still, one covering diabetic peripheral neuropathic pain toward 2020, another covering fibromyalgia toward 2026. None of these were salt-change patents; they were formulation and method-of-use layers filed around a salt that never changed. The comparison matters because a generic challenger evaluating Cymbalta’s real launch date had to track four separate patent categories with four separate obviousness standards, not one.<\/p>\n\n\n\n

                Salt Change vs. Fixed-Dose Combinations and Product Hopping<\/h4>\n\n\n\n
                Tactic<\/th>What Changes<\/th>Typical Legal Vulnerability<\/th><\/tr>
                Salt change<\/td>Counter-ion paired with the same active molecule<\/td>Obviousness, if the salt was one of a known, finite list of candidates<\/td><\/tr>
                Polymorph<\/td>Crystal form of the same molecule or salt<\/td>Obviousness or, outside the U.S., an enhanced-efficacy requirement<\/td><\/tr>
                Formulation patent<\/td>Delivery mechanism, such as delayed-release or extended-release<\/td>Obviousness over known formulation technology<\/td><\/tr>
                Method-of-use patent<\/td>A specific indication or dosing regimen<\/td>Vulnerable to skinny labeling and carve-outs by generic competitors<\/td><\/tr>
                Fixed-dose combination<\/td>Two active ingredients combined into one product<\/td>Product-hopping and antitrust scrutiny, separate from patent validity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

                Key Takeaways<\/h2>\n\n\n\n
                  \n
                • A salt patent survives obviousness challenge when the record shows a genuinely unpredictable technical benefit, not routine screening of a known list of candidates.<\/li>\n\n\n\n
                • Pfizer v. Apotex remains the controlling cautionary case: three district courts found the Norvasc besylate patent valid, and the Federal Circuit reversed all three based on Pfizer’s own lab records.<\/li>\n\n\n\n
                • Plavix and the Januvia DHP salt show the counter-pattern: salts tied to solving a real technical problem, chiral resolution or a documented stability gain, have been upheld even after Norvasc.<\/li>\n\n\n\n
                • India’s Section 3(d) imposes a stricter bar than U.S. obviousness law, rejecting incremental forms of known substances absent proven enhanced therapeutic efficacy.<\/li>\n\n\n\n
                • Late-stage salt patents sit inside a broader evergreening pattern; the best-selling U.S. drugs average well over a hundred patent filings each, most of them after FDA approval.<\/li>\n\n\n\n
                • For generic and biosimilar challengers, the strongest Paragraph IV targets are salt patents whose own prosecution history describes the salt as routine or interchangeable with what came before.<\/li>\n<\/ul>\n\n\n\n

                  Frequently Asked Questions<\/h2>\n\n\n\n

                  Is a salt change patent automatically invalid after Pfizer v. Apotex?<\/h3>\n\n\n\n

                  No. Pfizer v. Apotex invalidated one specific patent on specific facts. Salt patents decided since, including Merck’s Januvia DHP salt patent and Valeant’s bupropion salt patents, have been upheld where the evidence showed a real, unpredicted technical benefit.<\/p>\n\n\n\n

                  What is the difference between a salt patent and a polymorph patent?<\/h3>\n\n\n\n

                  A salt patent claims a new acid or base counter-ion paired with the active molecule. A polymorph patent claims a new crystal arrangement of the same molecule or salt, with no change to the underlying chemical composition.<\/p>\n\n\n\n

                  Why did Sanofi win the Plavix salt case when Pfizer lost the Norvasc case?<\/h3>\n\n\n\n

                  Plavix’s bisulfate salt was functionally tied to resolving a racemic mixture into its active enantiomer, a problem the prior art did not solve. Norvasc’s besylate salt was a straightforward swap on an already-isolated, already-characterized molecule with a prior genus claim already covering its acceptable salts.<\/p>\n\n\n\n

                  Does the FDA evaluate whether a new salt patent is legally valid before listing it in the Orange Book?<\/h3>\n\n\n\n

                  No. The FDA lists patents based on the sponsor’s certification that they claim the drug substance, drug product, or an approved method of use. It does not assess patent validity, which is why weak salt patents still trigger a 30-month stay if the patent holder sues within 45 days of a Paragraph IV notice.<\/p>\n\n\n\n

                  How long does a 30-month stay actually delay generic approval?<\/h3>\n\n\n\n

                  Up to 30 months from the date the patent holder received notice of the Paragraph IV certification, though the stay ends earlier if a court rules the patent invalid, not infringed, or unenforceable before that period runs out.<\/p>\n\n\n\n

                  Can a generic company launch before a salt patent case is fully resolved?<\/h3>\n\n\n\n

                  Yes, at risk, meaning the generic company proceeds without a final court ruling and accepts exposure to damages if it ultimately loses. Apotex’s at-risk launch of generic clopidogrel bisulfate cost it 442 million dollars once the Plavix patent was upheld.<\/p>\n\n\n\n

                  Why do so many blockbuster drugs have well over a hundred patents?<\/h3>\n\n\n\n

                  Independent analysis of top-selling U.S. drugs found an average of 125 patent applications filed and 71 granted per drug, with two-thirds of those applications filed after FDA approval, a pattern that spans salt patents, formulation patents, and method-of-use patents rather than any single tactic.<\/p>\n\n\n\n

                  Is India’s rejection of the Glivec polymorph patent a sign that all incremental drug patents fail there?<\/h3>\n\n\n\n

                  No. India’s Supreme Court explicitly stated that Section 3(d) does not bar all incremental pharmaceutical patents. It requires proof of significantly enhanced therapeutic efficacy over the correct known form, a bar Novartis did not clear for the beta-crystalline imatinib mesylate polymorph.<\/p>\n\n\n\n

                  What should a generic manufacturer look for before deciding whether to challenge a salt patent?<\/h3>\n\n\n\n

                  Whether an earlier patent already discloses a genus claim covering the parent compound’s acceptable salts, whether a standard salt-selection reference would have pointed toward the specific salt at issue, and whether the patentee’s own prosecution history or lab records describe the salt as offering a specific, unpredicted benefit or simply as one option among several routine candidates.<\/p>\n\n\n\n

                  Where can I track which patents are actually listed against a specific drug, including salt-form patents?<\/h3>\n\n\n\n

                  The FDA’s Orange Book is the primary source of record for drug substance, drug product, and method-of-use patent listings. Tools like DrugPatentWatch aggregate that data alongside litigation history and expiration analysis, which is useful when a drug carries several overlapping salt, formulation, and method-of-use patents with different expiration dates rather than one clean cutoff.<\/p>\n\n\n\n

                  References<\/h2>\n\n\n\n

                  [1] Pfizer, Inc. v. Apotex, Inc., 480 F.3d 1348 (Fed. Cir. 2007).
                  [2] Novartis AG v. Union of India, (2013) 6 SCC 1 (Supreme Court of India).
                  [3] Sanofi-Synthelabo v. Apotex, Inc., 470 F.3d 1368 (Fed. Cir. 2006).
                  [4] KSR International Co. v. Teleflex Inc., 550 U.S. 398 (2007).
                  [5] Takeda Chemical Industries, Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 1350 (Fed. Cir. 2007).
                  [6] I-MAK. (2022). Overpatented, Overpriced: How Excessive Pharmaceutical Patenting Extends Monopolies and Blocks Competition. Initiative for Medicines, Access & Knowledge.
                  [7] Merck Sharpe & Dohme Corp. and Merck Canada Inc. v. Pharmascience Inc., 2022 FC 417 (Federal Court of Canada).
                  [8] FTC v. Actavis, Inc., 570 U.S. 136 (2013).
                  [9] U.S. Food and Drug Administration. (2026). Patent Certifications and Suitability Petitions. FDA.gov.
                  [10] Sanofi and Bristol-Myers Squibb. (2012, February 8). Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex [Press release].
                  [11] Valeant Pharmaceuticals International, Inc. v. Watson Pharmaceuticals, Inc., appeal affirmed, Fed. Cir. (per curiam), affirming S.D. Fla. No. 10-20526, 2011 U.S. Dist. LEXIS 128742.
                  [12] Berge, S. M., Bighley, L. D., & Monkhouse, D. C. (1977). Pharmaceutical salts. Journal of Pharmaceutical Sciences, 66(1), 1-19.
                  [13] Intellectual Property Watch. (2013, April 4). The Judgment in Novartis v. India: What the Supreme Court of India Said.<\/p>\n","protected":false},"excerpt":{"rendered":"

                  A drug goes off patent. The originator swaps the salt form, files a new patent, and tells investors the franchise […]<\/p>\n","protected":false},"author":1,"featured_media":39412,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-39408","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39408","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=39408"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39408\/revisions"}],"predecessor-version":[{"id":39415,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39408\/revisions\/39415"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/39412"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=39408"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=39408"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=39408"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}